Drug Information
Drug (ID: DG00308) and It's Reported Resistant Information
Name |
Ampicillin
|
||||
---|---|---|---|---|---|
Synonyms |
ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
Click to Show/Hide
|
||||
Indication |
In total 1 Indication(s)
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(11 diseases)
Bacterial infection [ICD-11: 1A00-1C4Z]
[3]
Cholera [ICD-11: 1A00]
[4]
Escherichia coli intestinal infection [ICD-11: 1A03]
[3]
Non-tuberculous mycobacteria infection [ICD-11: 1B21]
[5]
Peritonitis [ICD-11: DC50]
[6]
Pharyngitis [ICD-11: CA02]
[7]
Pneumonia [ICD-11: CA40]
[8]
Shigellosis [ICD-11: 1A02]
[9]
Tissue pyogenic bacterial infection [ICD-11: 1B7Y]
[10]
Ulcer [ICD-11: EH90]
[5]
Urinary tract infection [ICD-11: GC08]
[11]
Disease(s) with Resistance Information Validated by in-vivo Model for This Drug
(2 diseases)
Escherichia coli intestinal infection [ICD-11: 1A03]
[12]
Periodontal disease [ICD-11: DA0C]
[13]
|
||||
Target | Bacterial Penicillin binding protein (Bact PBP) | NOUNIPROTAC | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
C16H19N3O4S
|
||||
IsoSMILES |
CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C
|
||||
InChI |
1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1
|
||||
InChIKey |
AVKUERGKIZMTKX-NJBDSQKTSA-N
|
||||
PubChem CID | |||||
ChEBI ID | |||||
TTD Drug ID | |||||
VARIDT ID | |||||
INTEDE ID | |||||
DrugBank ID |
Type(s) of Resistant Mechanism of This Drug
DISM: Drug Inactivation by Structure Modification
IDUE: Irregularity in Drug Uptake and Drug Efflux
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Cholera [ICD-11: 1A00]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Erythromycin esterase (EREA2) | [4] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Vibrio cholerae PL96 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA5, ereA2 lead to drug resistance. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Aminoglycoside (3'') (9) adenylyltransferase (AADA) | [4] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae O26 strain AS482 | 567107 | ||
Vibrio cholerae O39 strain AS634 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of aadA1-S lead to drug resistance. | |||
Key Molecule: Dihydrofolate reductase (DHFR) | [4] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae O62 strain AS438 | 666 | ||
Vibrio cholerae PG149a | 666 | |||
Vibrio cholerae PG224 | 666 | |||
Vibrio cholerae PG262(b) | 666 | |||
Vibrio cholerae PG9 | 666 | |||
Vibrio cholerae PG95 | 666 | |||
Vibrio cholerae PL1 | 666 | |||
Vibrio cholerae PL61 | 666 | |||
Vibrio cholerae PL78/6 | 666 | |||
Vibrio cholerae PL91 | 666 | |||
Vibrio cholerae PG92 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA1 lead to drug resistance. | |||
Key Molecule: Dihydrofolate reductase (DHFR) | [4] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio cholerae infection [ICD-11: 1A00.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio cholerae PG153/1 | 666 | ||
Vibrio cholerae PG170 | 666 | |||
Vibrio cholerae PL96 | 666 | |||
Experiment for Molecule Alteration |
PCR and DNA sequencing assay | |||
Experiment for Drug Resistance |
Commercial antimicrobial discs assay | |||
Mechanism Description | The expression of dfrA15 lead to drug resistance. |
Bacterial infection [ICD-11: 1A00-1C4Z]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Beta-lactamase (BLA) | [1], [2] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Mycobacterium tuberculosis H37Rv | 83332 | ||
Escherichia coli DH10B | 316385 | |||
Mycobacterium smegmatis PM274 | 1772 | |||
Mycobacterium smegmatis PM759 | 1772 | |||
Mycobacterium smegmatis PM791 | 1772 | |||
Mycobacterium smegmatis PM876 | 1772 | |||
Mycobacterium smegmatis PM939 | 1772 | |||
Mycobacterium smegmatis PM976 | 1772 | |||
Mycobacterium tuberculosis PM638 | 1773 | |||
Mycobacterium tuberculosis PM669 | 1773 | |||
Mycobacterium tuberculosis PM670 | 1773 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Disk diffusion test assay; E-strip test assay | |||
Mechanism Description | Mycobacteria produce Beta-lactamases and are intrinsically resistant to Beta-lactam antibiotics.The mutants M. tuberculosis PM638 (detablaC1) and M. smegmatis PM759 (detablaS1) showed an increase in susceptibility to Beta-lactam antibiotics. | |||
Key Molecule: Beta-lactamase (BLA) | [14], [15] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli HB101 | 634468 | ||
Escherichia coli JM101 | 562 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Mechanism Description | Beta-lactamases (Beta-lactamhydrolase, EC 3.5.2.6), responsible for most of the resistance to Beta-lactam antibiotics, are often plasmid mediated.The OXA-1 beta-lactamase gene is part of Tn2603, which is borne on the R plasmid RGN238. | |||
Key Molecule: Beta-lactamase (BLA) | [15], [16], [17] | |||
Molecule Alteration | Missense mutation | p.L76N+p.V84I+p.A184V |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli JM109 | 562 | ||
Mechanism Description | The TEM Beta-lactamases are among the best-studied antibiotic resistance enzymes around.TEM-1, the first TEM allele identified, was isolated from penicillin-resistant bacteria in 1963. | |||
Key Molecule: Beta-lactamase (BLA) | [15], [16], [17] | |||
Molecule Alteration | Missense mutation | p.L76N |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli JM109 | 562 | ||
Mechanism Description | The TEM Beta-lactamases are among the best-studied antibiotic resistance enzymes around.TEM-1, the first TEM allele identified, was isolated from penicillin-resistant bacteria in 1963. | |||
Key Molecule: Beta-lactamase (BLA) | [18] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Pseudomonas aeruginosa infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Pseudomonas aeruginosa PAO1 | 208964 | ||
Experiment for Molecule Alteration |
DNA sequencing and protein assay | |||
Experiment for Drug Resistance |
Disk diffusion assay | |||
Mechanism Description | P. aeruginosa harbors two naturally encoded Beta-lactamase genes, one of which encodes an inducible cephalosporinase and the other of which encodes a constitutively expressed oxacillinase. OXA-50 is a kind of oxacillinase which lead to drug resistance. | |||
Key Molecule: Aminoglycoside acetyltransferase (AAC) | [19] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Vibrio fluvialis infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Vibrio fluvialis H-08942 | 676 | ||
Experiment for Molecule Alteration |
PCR; DNA sequencing assay; Southern hybridization assay; Cloning and expression assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Aac(3)-Id is a new type of aminoglycoside acetyltransferase gene which causes drug resistance. | |||
Key Molecule: Metallo-beta-lactamase (VIM1) | [3] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Achromobacter xylosoxydans infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli | 668369 | ||
Achromobacter xylosoxydans subsp. denitrificans AX-22 | 85698 | |||
Escherichia coli MkD-135 | 562 | |||
Pseudomonas aeruginosa 10145/3 | 287 | |||
Experiment for Molecule Alteration |
DNA extraction and Sequencing assay | |||
Experiment for Drug Resistance |
Macrodilution broth method assay | |||
Mechanism Description | A. xylosoxydans AX22 exhibited broad-spectrum resistance to Beta-lactams and aminoglycosides. The Beta-lactam resistance pattern (including piperacillin, ceftazidime, and carbapenem resistance) was unusual for this species, and the high-level carbapenem resistance suggested the production of an acquired carbapenemase. In fact, carbapenemase activity was detected in a crude extract of AX22 (specific activity, 184 +/- 12 U/mg of protein), and this activity was reduced (>80%) after incubation of the crude extract with 2 mM EDTA, suggesting the presence of a metallo-Beta-lactamase determinant. | |||
Key Molecule: Beta-lactamase (BLA) | [15], [20] | |||
Molecule Alteration | Missense mutation | p.V77A+p.D114N+p.S140A+p.N288D |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Citrobacter freundii strain 2524/96 | 546 | ||
Citrobacter freundii strain 2525/96 | 546 | |||
Citrobacter freundii strain 2526/96 | 546 | |||
Escherichia coli strain 2527/96 | 562 | |||
Experiment for Drug Resistance |
Agar dilution method assay | |||
Mechanism Description | Sequencing has revealed that C. freundii isolates produced a new CTX-M-3 enzyme which is very closely related to the CTX-M-1/MEN-1 Beta-lactamase. | |||
Key Molecule: Imipenem-hydrolyzing beta-lactamase (NMCA) | [21] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Enterobacter cloacae infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli strain JM109 | 83333 | ||
Enterobacter cloacae strain NOR-1 | 550 | |||
Experiment for Molecule Alteration |
Dideoxynucleotide chain-termination method assay | |||
Experiment for Drug Resistance |
MIC assay | |||
Mechanism Description | Here we report a gene encoding a carbapenemase, which was cloned from the chromosome of a clinical isolate of Enterobacter cloacae, strain NOR-1, into pACYC184 plasmid in Escherichia coli. Unlike all the sequenced carbapenemases, which are class B metallo-beta-lactamases, the mature protein (NmcA) is a class A serine beta-lactamase. NmcA shares the highest amino acid identity (50%) with the extended-spectrum class A beta-lactamase MEN-1 from Escherichia coli. | |||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: ABC transporter ATPase subunit (ABCS) | [22], [23], [24] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Enterococcus faecalis isolates | 1351 | ||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Multidrug efflux pump extraction, purification, and sequencing showed the distribution of mefA and msrA/msrB efflux pumps. | |||
Key Molecule: Putative ABC transporter ATP-binding component (OTRC) | [25] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli BL21 (DE3) | 469008 | ||
Escherichia coli | 668369 | |||
Escherichia coli ET12567 (pUZ8002) | 562 | |||
Streptomyces rimosus M4018 | 1927 | |||
Streptomyces rimosus SR16 | 1927 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay; Allelic frequency measurement assay | |||
Experiment for Drug Resistance |
MIC assay | |||
Mechanism Description | OtrC is a multidrug resistance protein based on an ATP hydrolysis-dependent active efflux mechanism.OtrC is a multidrug resistance protein based on an ATP hydrolysis-dependent active efflux mechanism. |
Escherichia coli intestinal infection [ICD-11: 1A03]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Beta-lactamase (BLA) | [26] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Escherichia coli infection [ICD-11: 1A03.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli Co227 | 562 | ||
Escherichia coli Co228 | 562 | |||
Escherichia coli Co356 | 562 | |||
Experiment for Molecule Alteration |
PCR; PCR-restriction fragment length polymorphism analysis; Sequencing assay | |||
Experiment for Drug Resistance |
Agar dilution method assay | |||
Mechanism Description | Multiple-antibiotic-resistant phenotype is associated with gene mutation and mar locus regulation. | |||
Key Molecule: Beta-lactamase (BLA) | [26] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Escherichia coli infection [ICD-11: 1A03.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli Co227 | 562 | ||
Escherichia coli Co228 | 562 | |||
Escherichia coli Co356 | 562 | |||
Experiment for Molecule Alteration |
PCR; PCR-restriction fragment length polymorphism analysis; Sequencing assay | |||
Experiment for Drug Resistance |
Agar dilution method assay | |||
Mechanism Description | Multiple-antibiotic-resistant phenotype is associated with gene mutation and mar locus regulation. | |||
Key Molecule: Metallo-beta-lactamase (VIM1) | [3] | |||
Molecule Alteration | Expression | Acquired |
||
Resistant Disease | Escherichia coli infection [ICD-11: 1A03.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli | 668369 | ||
Achromobacter xylosoxydans subsp. denitrificans AX-22 | 85698 | |||
Escherichia coli MkD-135 | 562 | |||
Pseudomonas aeruginosa 10145/3 | 287 | |||
Experiment for Molecule Alteration |
DNA extraction and Sequencing assay | |||
Experiment for Drug Resistance |
Macrodilution broth method assay | |||
Mechanism Description | Electroporation of Escherichia coli DH5alpha with the purified plasmid preparation yielded ampicillin-resistant transformants which contained a plasmid apparently identical to pAX22 (data not shown). DH5alpha(pAX22) produced carbapenemase activity (specific activity of crude extract, 202 +/- 14 U/mg of protein) and, compared to DH5alpha, exhibited a decreased susceptibility to several Beta-lactams. | |||
Key Molecule: Beta-lactamase (BLA) | [12] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Escherichia coli infection [ICD-11: 1A03.0] | |||
Experimental Note | Discovered Using In-vivo Testing Model | |||
In Vitro Model | Escherichia coli | 668369 | ||
Escherichia coli strain HB101 | 634468 | |||
Escherichia coli strain JC2926 | 562 | |||
Experiment for Molecule Alteration |
DNA sequencing assay | |||
Mechanism Description | SHV Beta-lactamases confer resistance to a broad spectrum of Beta-lactam antibiotics and are of great therapeutic concern for infections caused by many species of the family Enterobacteriaceae. SHV-1, the original member of the SHV Beta-lactamase family, is present in most strains of Klebsiella pneumoniae and may be either chromosomally or plasmid mediated. A plasmid-mediated SHV-1 is also commonly found in Escherichia coli and is seen in other genera as well. | |||
Key Molecule: Aminoglycoside 3'-phosphotransferase (A3AP) | [27] | |||
Molecule Alteration | Expression | Acquired |
||
Resistant Disease | Escherichia coli infection [ICD-11: 1A03.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli HB101 | 634468 | ||
Escherichia coli strain JM103 | 83333 | |||
Bacillus circulans strain | 1397 | |||
Streptomyces lividans strain 66 | 1200984 | |||
Streptomyces lividans strain M180 | 1916 | |||
Experiment for Molecule Alteration |
DNA sequencing assay | |||
Experiment for Drug Resistance |
Semi-quantitative phosphocellulose-paper binding assay method assay | |||
Mechanism Description | The previous demonstration that the APH gene of B. circulans could be expressed in E.coli. These contained a 5.5kb Hind3-digest insert (pCH4) or a 2.7kb Sal1-digest insert (pCH5) at the corresponding site in pBR322. Both these derivatives expressed ampicillin and ribostamycin resistance in E.coli. |
Non-tuberculous mycobacteria infection [ICD-11: 1B21]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: OXA-23 carbapenemase (BLA OXA-23) | [28] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Cutaneous bacterial infection [ICD-11: 1B21.4] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Acinetobacter baumannii isolates | 470 | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
Broth microdilution method assay; Agar dilution method assay | |||
Mechanism Description | The isolate was resistant to antibiotics other than ampicillin-sulbactam and colistin, suggesting drug resistance due to carbapenemase production by OXA-23.carbapenem resistance in the isolated carbapenem-resistant A. baumannii strain was at least partially conferred by bla OXA-23-like carbapenemase. |
Tissue pyogenic bacterial infection [ICD-11: 1B7Y]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [10] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Staphylococcus infection [ICD-11: 1B7Y.3] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Pseudomonas aeruginosa isolates | 287 | ||
Staphylococcus aureus isolates | 1280 | |||
Klebsiella pneumoniae isolates | 573 | |||
Acinetobacter isolates | 469 | |||
Enterobacter cloacae isolates | 550 | |||
Experiment for Drug Resistance |
Disk diffusion method assay | |||
Mechanism Description | Up-regulation of P-glycoprotein led to ampicillin resistance in the staphylococcus infection. |
ICD-13: Digestive system diseases
Periodontal disease [ICD-11: DA0C]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Beta-lactamase (Q9X4S7) | [13] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Chronic periodontitis [ICD-11: DA0C.Y] | |||
Experimental Note | Discovered Using In-vivo Testing Model | |||
In Vitro Model | Prevotella nigrescens strain | 28133 | ||
Experiment for Molecule Alteration |
PCR | |||
Experiment for Drug Resistance |
Disc diffusion test | |||
Mechanism Description | Seventy five percent of patients carried two species of beta-lactamase-producing anaerobic bacteria that comprised 9.4% of the total number of cultivable bacteria. Fifty one percent of beta-lactamase-producing strains mainly Prevotella, Porphyromonas, and Bacteroides carried the cfxA gene, whereas none of them carried blaTEM. Further characterization of the cfxA gene showed that 76.7% of these strains carried the cfxA2 gene, 14% carried cfxA3, and 9.3% carried cfxA6. The cfxA6 gene was present in three Prevotella spp. and in one Porphyromonas spp. Strains containing cfxA genes (56%) were resistant to the beta-lactam antibiotics. | |||
Key Molecule: Beta-lactamase (Q9X4S7) | [13] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Chronic periodontitis [ICD-11: DA0C.Y] | |||
Experimental Note | Discovered Using In-vivo Testing Model | |||
In Vitro Model | Porphyromonas gingivalis strain | 837 | ||
Experiment for Molecule Alteration |
PCR | |||
Experiment for Drug Resistance |
Disc diffusion test | |||
Mechanism Description | Seventy five percent of patients carried two species of beta-lactamase-producing anaerobic bacteria that comprised 9.4% of the total number of cultivable bacteria. Fifty one percent of beta-lactamase-producing strains mainly Prevotella, Porphyromonas, and Bacteroides carried the cfxA gene, whereas none of them carried blaTEM. Further characterization of the cfxA gene showed that 76.7% of these strains carried the cfxA2 gene, 14% carried cfxA3, and 9.3% carried cfxA6. The cfxA6 gene was present in three Prevotella spp. and in one Porphyromonas spp. Strains containing cfxA genes (56%) were resistant to the beta-lactam antibiotics. |
ICD-16: Genitourinary system diseases
Urinary tract infection [ICD-11: GC08]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Aminoglycoside (3'') (9) adenylyltransferase (AADA) | [11] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Urinary tract infection [ICD-11: GC08.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli serogroup O11 | 1095705 | ||
Escherichia coli serogroup O17 | 1010800 | |||
Escherichia coli serogroup O73 | 2170725 | |||
Escherichia coli serogroup O77 | 562 | |||
Experiment for Molecule Alteration |
PCR amplification and sequence alignments assay | |||
Experiment for Drug Resistance |
Microdilution method assay | |||
Mechanism Description | All the UTI outbreak CgA strains in this study contained the same class 1 integron dfrA17-aadA5 gene cassette arrangement with 100% sequence match, suggesting clonal spread of the bacterial strain itself. While aminoglycoside adenyltransferase A (aadA ) and dihydrofolate reductase A (dfrA ), encoding resistance to streptomycin and trimethoprim. | |||
Key Molecule: Aminoglycoside (3'') (9) adenylyltransferase (AADA) | [11] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Urinary tract infection [ICD-11: GC08.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli serogroup O11 | 1095705 | ||
Escherichia coli serogroup O17 | 1010800 | |||
Escherichia coli serogroup O73 | 2170725 | |||
Escherichia coli serogroup O77 | 562 | |||
Experiment for Molecule Alteration |
PCR amplification and sequence alignments assay | |||
Experiment for Drug Resistance |
Microdilution method assay | |||
Mechanism Description | All the UTI outbreak CgA strains in this study contained the same class 1 integron dfrA17-aadA5 gene cassette arrangement with 100% sequence match, suggesting clonal spread of the bacterial strain itself. While aminoglycoside adenyltransferase A (aadA ) and dihydrofolate reductase A (dfrA ), encoding resistance to streptomycin and trimethoprim. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Dihydrofolate reductase (DHFR) | [11] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Urinary tract infection [ICD-11: GC08.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli serogroup O11 | 1095705 | ||
Escherichia coli serogroup O17 | 1010800 | |||
Escherichia coli serogroup O73 | 2170725 | |||
Escherichia coli serogroup O77 | 562 | |||
Experiment for Molecule Alteration |
PCR amplification and sequence alignments assay | |||
Experiment for Drug Resistance |
Microdilution method assay | |||
Mechanism Description | All the UTI outbreak CgA strains in this study contained the same class 1 integron dfrA17-aadA5 gene cassette arrangement with 100% sequence match, suggesting clonal spread of the bacterial strain itself. While aminoglycoside adenyltransferase A (aadA ) and dihydrofolate reductase A (dfrA ), encoding resistance to streptomycin and trimethoprim. | |||
Key Molecule: Dihydrofolate reductase (DHFR) | [11] | |||
Molecule Alteration | Expression | Inherence |
||
Resistant Disease | Urinary tract infection [ICD-11: GC08.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli serogroup O11 | 1095705 | ||
Escherichia coli serogroup O17 | 1010800 | |||
Escherichia coli serogroup O73 | 2170725 | |||
Escherichia coli serogroup O77 | 562 | |||
Experiment for Molecule Alteration |
PCR amplification and sequence alignments assay | |||
Experiment for Drug Resistance |
Microdilution method assay | |||
Mechanism Description | All the UTI outbreak CgA strains in this study contained the same class 1 integron dfrA17-aadA5 gene cassette arrangement with 100% sequence match, suggesting clonal spread of the bacterial strain itself. While aminoglycoside adenyltransferase A (aadA ) and dihydrofolate reductase A (dfrA ), encoding resistance to streptomycin and trimethoprim. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.